COVID-19 after BNT162b2 two-dose primary series does not improve the efficacy of a booster dose in nursing home residents

Clin Transl Allergy. 2023 Mar;13(3):e12224. doi: 10.1002/clt2.12224.

Authors

Hubert Blain¹, Edouard Tuaillon², Lucie Gamon³, Amandine Pisoni², Safa Aouinti³, Marie-Christine Picot³, Jean Bousquet⁴

Affiliations

¹ Department of Internal Medicine and Geriatrics, MUSE University, Montpellier, France.
² INSERM U 1058/EFS, University Hospital, Montpellier, France.
³ Clinical Research and Epidemiology Unit, University Hospital, Montpellier, France.
⁴ Department of Dermatology and Allergy, Universitätsmedizin, Berlin, Germany.

No abstract available

Keywords: BNT162b2 vaccine; SARS-CoV-2 spike antibodies; boost vaccine dose; nursing home residents.

Publication types

Letter